Pfizer loses court battle to keep its Vyndaqel copay assistance for Medicare patients—again

Pfizer has tried to clear the name of its copay assistance programs for pricey heart drugs Vyndaqel and Vyndamax. But a federal appeals court didn't buy the argument.